Serina Therapeutics, Inc.
$2.1
0%
2026-04-21 09:22:00
serinatherapeutics.com
ASE: SER
Explore Serina Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.86 M
Current Price
$2.1
52W High / Low
$7.92 / $1.22
Stock P/E
—
Book Value
$-0.46
Dividend Yield
—
ROCE
-709.03%
ROE
-81.59%
Face Value
—
EPS
$-1.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
0.1
Debt / Equity
-84.92
Current Ratio
1.71
Quick Ratio
1.71
Forward P/E
-1.89
Price / Sales
187.55
Enterprise Value
$29.59 M
EV / EBITDA
-1.24
EV / Revenue
227.61
Rating
Strong Buy
Target Price
$11
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Outlook Therapeutics, Inc. | $0.37 | — | $38.71 M | — | 246.27% | 118.61% | $3.39 / $0.16 | $-0.6 |
| 2. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 3. | Sana Biotechnology, Inc. | $3.82 | — | $939.37 M | — | -60.83% | -1.19% | $6.55 / $1.53 | $0.6 |
| 4. | Palisade Bio, Inc. | $2.5 | — | $414.71 M | — | -13.92% | -24.52% | $2.64 / $0.53 | $0.81 |
| 5. | 4D Molecular Therapeutics, Inc. | $10.07 | — | $535.53 M | — | -30.52% | -27.57% | $12.34 / $2.88 | $8.78 |
| 6. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
| 7. | Coya Therapeutics, Inc. | $4.99 | — | $112.13 M | — | -51.17% | -51.39% | $7.75 / $3.71 | $2.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -6.21 M | -6.39 M | -5.57 M | -5.86 M | -5.55 M | — |
| Net Profit | -3.34 M | -4.58 M | -6.45 M | -4.81 M | -2.74 M | — |
| EPS in Rs | -0.27 | -0.37 | -0.52 | -0.39 | -0.22 | 0.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 3 M | 0.5 M |
| Operating Profit | -24.02 M | -17.05 M | -3.13 M | -2.27 M |
| Net Profit | -19.18 M | -11.14 M | 5.27 M | -2.68 M |
| EPS in Rs | -1.56 | -0.9 | 0.43 | -0.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.95 M | 6.72 M | 8.97 M | 0.86 M |
| Total Liabilities | 6.99 M | 6.22 M | 41.26 M | 38.64 M |
| Equity | -0.04 M | 0.64 M | -32.29 M | -37.78 M |
| Current Assets | 6.08 M | 5.68 M | 7.62 M | 0.55 M |
| Current Liabilities | 3.56 M | 2.37 M | 1.41 M | 0.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -17.95 M | -17.14 M | -2.48 M | -2.08 M |
| Investing CF | -0.06 M | -0.02 M | -0.5 M | 0.98 M |
| Financing CF | 17.41 M | 13.21 M | 10.07 M | 1.31 M |
| Free CF | -18.01 M | -17.16 M | -2.98 M | -2.09 M |
| Capex | -0.06 M | -0.02 M | -0.5 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | 500% | — | — |
| Earnings Growth % | -311.44% | 296.45% | — | — |
| Profit Margin % | — | 175.63% | -536.42% | — |
| Operating Margin % | — | -104.3% | -454.07% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | 197.23% | -520.99% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-03-15 | 1:0.028 |